NEOG — Neogen Corporation

Is NEOG overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Overbought As of August 19, 2026

Neogen Corporation (NEOG) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $11.57. The rating moved from Neutral to Overbought on August 12, 2026.

See all overbought Healthcare stocks →

AI analysis

Neogen Corporation (NEOG) operates a diversified suite of food-safety and animal-health testing and consumable products that generate recurring revenue and exhibit margin durability. The company benefits from regulatory-driven demand and entrenched distribution, with moderate growth from product innovation and selective strategic investments. Near-term performance will be influenced by agricultural cycle dynamics, input-cost pressures, and the macro environment around inflation/data releases. Social and research signals are limited but retail sentiment appears cautiously optimistic. Key risks include competitive pressures, supply-chain and regulatory execution, and sensitivity to end-market cyclicality. Base-case outlook is steady revenue with modest upside from new products and operational leverage, while downside scenarios stem from demand softness or material execution setbacks.

Key factors

  • Diversified food-safety and animal-safety product portfolio with recurring consumables and testing reagents that support steady revenue streams
  • Established global distribution channels and long-term customer relationships in food processing, agriculture and veterinary markets
  • Margin resilience driven by consumable repeat purchases and cost controls, with potential for incremental operational leverage
  • Exposure to steady demand for food safety testing due to regulatory requirements and ongoing supply-chain quality controls
  • Moderate balance-sheet flexibility to fund product development and selective M&A, supporting niche capability expansion
  • Market backdrop showing mild risk-on flows into equities; limited sector-specific social sentiment available but retail chatter is cautiously optimistic

Risks

  • Cyclicality in agricultural and food-processing end markets, which can depress order volumes during downturns
  • Competitive pressure from larger diagnostics and animal-health firms, creating pricing and market-share risk
  • Supply-chain disruptions or raw-material cost inflation that could squeeze margins or delay shipments
  • Regulatory or compliance issues tied to testing products could harm reputation and sales if incidents occur
  • Currency and international exposure risk given global distribution footprint
  • Execution risk on new product commercialization or integration risks from any acquisitions
  • Near-term macro sensitivity — weaker discretionary spending or tighter credit conditions could slow institutional purchasing

See today's live rating, score and targets

Members see the live hourly rating for NEOG — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.